10-15-2013

Recombinant AAV-Mediated $BEST1$ Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal Effects

Karina E. Guziewicz  
*University of Pennsylvania*, karinag@vet.upenn.edu

Barbara Zangerl  
*University of Pennsylvania*, bzangerl@vet.upenn.edu

András M. Komáromy  
*University of Pennsylvania*, komaromy@vet.upenn.edu

Simone Iwabe

Vincent A. Chiodo

*See next page for additional authors*

Follow this and additional works at: [https://repository.upenn.edu/vet_papers](https://repository.upenn.edu/vet_papers)

Part of the Genetics Commons, Ophthalmology Commons, and the Veterinary Medicine Commons

**Recommended Citation**

Guziewicz, K. E., Zangerl, B., Komáromy, A. M., Iwabe, S., Chiodo, V. A., Boye, S. L., Hauswirth, W. W., Beltran, W., & Aguirre, G. D. (2013). Recombinant AAV-Mediated $BEST1$ Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal Effects. *PLoS ONE, 8*(10), e75666-. [http://dx.doi.org/10.1371/journal.pone.0075666](http://dx.doi.org/10.1371/journal.pone.0075666)

This paper is posted at ScholarlyCommons. [https://repository.upenn.edu/vet_papers/72](https://repository.upenn.edu/vet_papers/72)

For more information, please contact repository@pobox.upenn.edu.
Recombinant AAV-Mediated BEST1 Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal Effects

Abstract
Mutations in the BEST1 gene constitute an underlying cause of juvenile macular dystrophies, a group of retinal disorders commonly referred to as bestrophinopathies and usually diagnosed in early childhood or adolescence. The disease primarily affects macular and paramacular regions of the eye leading to major declines in central vision later in life. Currently, there is no cure or surgical management for BEST1-associated disorders. The recently characterized human disease counterpart, canine multifocal retinopathy (cmr), recapitulates a full spectrum of clinical and molecular features observed in human bestrophinopathies and offers a valuable model system for development and testing of therapeutic strategies. In this study, the specificity, efficiency and safety of rAAV-mediated transgene expression driven by the human VMD2 promoter were assessed in wild-type canine retinas. While the subretinal delivery of rAAV2/1 vector serotype was associated with cone damage in the retina when BEST1 and GFP were co-expressed, the rAAV2/2 vector serotype carrying either GFP reporter or BEST1 transgene under control of human VMD2 promoter was safe, and enabled specific transduction of the RPE cell monolayer that was stable for up to 6 months post injection. These encouraging studies with the rAAV2/2 vector lay the groundwork for development of gene augmentation therapy for human bestrophinopathies.

Keywords
mutations, retinal pigment, BEST1, canine multifocal retinopathy

Disciplines
Genetics | Medicine and Health Sciences | Ophthalmology | Veterinary Medicine

Author(s)
Karina E. Guziewicz, Barbara Zangerl, András M. Komáromy, Simone Iwabe, Vincent A. Chiodo, Sanford L. Boye, William W. Hauswirth, William Beltran, and Gustavo D. Aguirre

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/vet_papers/72
Recombinant AAV-Mediated BEST1 Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal Effects

Karina E. Guziewicz¹,², Barbara Zangerl¹,², Andreas M. Komárny¹,³, Simone Iwabe¹, Vincent A. Chiodo⁴, Sanford L. Boye⁴, William W. Hauswirth⁴, William A. Beltran¹, Gustavo D. Aguirre¹

Introduction

Disease-causing mutations in retinal pigment epithelium (RPE) and photoreceptor specific genes are a major cause of vision impairment worldwide. This is particularly devastating when the genetic alteration leads to a phenotype that affects foveal vision early in life and there are no treatment options available. Affected children and adolescents gradually lose central visual acuity that seriously impairs their quality of life in adulthood. The disease primarily affects macular and paramacular regions of the eye leading to major declines in central vision later in life. Currently, there is no cure or surgical management for BEST1-associated disorders. The recently characterized human disease counterpart, canine multifocal retinopathy (cmr), recapitulates a full spectrum of clinical and molecular features observed in human bestrophinopathies and offers a valuable model system for development and testing of therapeutic strategies. In this study, the specificity, efficiency and safety of rAAV-mediated transgene expression driven by the human VMD2 promoter were assessed in wild-type canine retinae. While the subretinal delivery of rAAV2/1 vector serotype was associated with cone damage in the retina when BEST1 and GFP were co-expressed, the rAAV2/2 vector serotype carrying either GFP reporter or BEST1 transgene under control of human VMD2 promoter was safe, and enabled specific transduction of the RPE cell monolayer that was stable for up to 6 months post injection. These encouraging studies with the rAAV2/2 vector lay the groundwork for development of gene augmentation therapy for human bestrophinopathies.

Abstract

Mutations in the BEST1 gene constitute an underlying cause of juvenile macular dystrophies, a group of retinal disorders commonly referred to as bestrophinopathies and usually diagnosed in early childhood or adolescence. The disease primarily affects macular and paramacular regions of the eye leading to major declines in central vision later in life. Currently, there is no cure or surgical management for BEST1-associated disorders. The recently characterized human disease counterpart, canine multifocal retinopathy (cmr), recapitulates a full spectrum of clinical and molecular features observed in human bestrophinopathies and offers a valuable model system for development and testing of therapeutic strategies. In this study, the specificity, efficiency and safety of rAAV-mediated transgene expression driven by the human VMD2 promoter were assessed in wild-type canine retinae. While the subretinal delivery of rAAV2/1 vector serotype was associated with cone damage in the retina when BEST1 and GFP were co-expressed, the rAAV2/2 vector serotype carrying either GFP reporter or BEST1 transgene under control of human VMD2 promoter was safe, and enabled specific transduction of the RPE cell monolayer that was stable for up to 6 months post injection. These encouraging studies with the rAAV2/2 vector lay the groundwork for development of gene augmentation therapy for human bestrophinopathies.
The cmr disorder results from any of the three distinct mutations identified to date in canine BEST1 (cBEST1) that model all major aspects of known disease-associated mutations and their molecular consequences described in man: cmr1 (C73T/R25X), an early stop mutation resulting in Best1 null phenotype; cmr2 (G482A/G161D), a missense change affecting protein folding and trafficking; and cmr3 (C1388del/P463fs), a frameshift mutation truncating the bestrophin1 C-terminus [11–14]. Since its discovery, cmr has been recognized as an important animal model for human bestrophinopathies suitable not only for carrying out mechanistic studies, but also for development and testing of therapeutic strategies such as recombinant adeno-associated virus (rAAV) based gene augmentation therapy.

Over the last decade, rAAV vectors have been proven safe in ocular tissue, and their versatility increased their use as gene delivery tools. Successful outcomes from the first clinical trials in patients affected with RPE65 forms of LCA were reported and have shown safety and efficacy [15–18]. While the rAAV2/2 serotype is the most widely used rAAV vector in preclinical and clinical trials when targeting the RPE, the rAAV2/1 serotype, which has also been shown to target this cell population [19], is thought to be more RPE-specific [20]. In preparation for gene augmentation therapy in cmr-affected dogs that could ultimately be translated to human BEST1-associated disorders, we compared the rAAV2/1 and rAAV2/2 vector serotypes carrying GFP reporter or BEST1 transgene under control of human VMD2 promoter (hVMD2). The onset, efficiency and stability of transgene expression, as well as the potential adverse effects of a single subretinal injection with either vector serotype, were evaluated in wild-type canine eyes. Our findings provide evidence that the rAAV2/1-mediated delivery of the BEST1 transgene potentially can cause cone-selective damage in the transduced retina. In contrast, the rAAV2/2 vector serotype is safe, specific, stable, and should be considered further for developing gene augmentation therapies in bestrophinopathies.

Results

A set of eighteen eyes from twelve dogs was used to determine the cell specificity and level of rAAV-mediated GFP expression regulated by the hVMD2 promoter in the normal canine retina. The rAAV2/1 or rAAV2/2 vector serotypes encoding GFP reporter gene under control of hVMD2 promoter (Fig. S1A) were delivered by subretinal injection (Fig. 1, Tab. S1). Immediately after vector administration, formation of the characteristic bleb underlying the neural retina was observed, delimiting the injected area of the fundus (Fig. 1 insert). In all cases, the retinal detachment completely resolved within 24 hours post injection (p.i.), and only the focal retinotomy scar remained visible. By autofluorescence imaging, GFP expression was first detectable at 2 weeks p.i., and reached its expression peak between 4 – 6 weeks p.i. (Fig. 1). The results obtained for rAAV2/1-hVMD2-GFP and rAAV2/2-hVMD2-GFP were comparable and clinical assessments throughout the injection-endpoint evaluation period did not reveal any abnormalities with either vector construct in any of the injected eyes.

Under control of the hVMD2 promoter, both vector serotypes demonstrated specific and exclusive cellular tropism for the RPE cell monolayer where the GFP reporter expression was detectable as native green fluorescence that colocalized with specific anti-GFP antibody labeling (Figs. 2, 3 and S2). In all cases, the extent of GFP expression in the RPE corresponded to the vector bleb area recorded immediately after subretinal injection. The gradual increase of GFP expression levels over the first 6 weeks p.i., and its stability up to 6 months after vector administration, were confirmed by immunohistochemical staining (Fig. 2). When taking into account the differences in total vector genomes injected, the transduction efficiency was qualitatively comparable between rAAV2/1 and rAAV2/2 serotypes (Fig. S2). Structural preservation of the retina was assessed by immunocytochemical staining 6 weeks p.i. using several RPE (Best1, RPE65) and cone (hCAR, L/M& S opsin) and rod (Rho) specific markers (Fig. 3). In all instances, retinal structure was normal, and showed no damage to the RPE or photoreceptor cells based on immunolabeling and by H&E staining (Fig. 3A,B). Overall, there was no difference observed in the transduction efficiency, onset or stability between rAAV2/1 and rAAV2/2 serotypes carrying the reporter gene and, most importantly, no adverse effects were noted with either vector secondary to the subretinal injection. Together, these findings provided evidence that human VMD2 promoter drives stable and specific transgene expression to the RPE cells in vivo after single injection of rAAV2/1-hVMD2-GFP or rAAV2/2-hVMD2-GFP vectors.

Subsequently, a modified vector construct encoding full-length canine or human BEST1 cDNA driven by the same promoter (Fig. S1B) was used to test rAAV-mediated BEST1 transgene expression in wild-type canine retinas. The vector dosage was 7.10×10^10 – 2.00×10^11 vg and 3.92×10^11 – 1.00×10^12 vg injected for rAAV2/1-hVMD2-BEST1 and rAAV2/2-hVMD2-BEST1, respectively (Tab. S1). In addition, to monitor the bleb kinetics and the spatial extent of a single subretinal injection, the rAAV2/1-hVMD2-BEST1 vector constructs were spiked with the corresponding GFP expressing vector at an average titer of 2.5×10^9 vg/ml (Tab. S1, Fig. S3).

For this study, a total of 11 normal eyes from eleven control dogs were subretinally injected with rAAV2/1 or rAAV2/2 carrying wild-type canine or human BEST1 and evaluated at several time points p.i. (Tab. S1). Similar to the prior reporter gene studies, the subretinal injection bleb resolved within 24 hours p.i. and the corresponding bleb boundaries were detectable by near-infrared reflectance imaging up to 4 weeks after vector administration (Fig. 4A). For the rAAV2/1-GFP-spiked injections, discrete areas of fluorescence were clearly visible in the autofluorescence mode over a 6 week monitoring period (Figs. 4A, S3). Again, all eyes used in this phase of experiment appeared clinically asymptomatic after the retinal reattachment and no obvious changes were noted throughout the observation period by routine fundus examination. The in vivo OCT imaging did not reveal changes in the retinal structure for any of the injected eyes, and, with either vector; the retinal thickness profiles were normal, and not different between the injected and non-injected regions (Fig. 4B).

The rAAV-mediated cBEST1 transgene expression in the normal canine retina was evaluated 4- and 6 weeks and 6 months p.i. (Tab. S1). While the endogenous expression of Best1 was limited to the basolateral plasma membrane, the transgene protein - found only in the bleb area - was localized within the RPE cell cytoplasm as a result of vector mediated overexpression; the results were the same with either vector (Fig. 5 illustrates the findings with rAAV2/2). The consequences of rAAV2/1- and AAV2/2-induced cBEST1 expression in the normal retina were compared at 4 weeks p.i., and retinal preservation was assessed by H&E staining and cell-specific immunolabeling (Fig. 6). Even though the H&E staining did not indicate any morphological abnormalities with either vector serotype, specific immunolabeling and fluorescence microscopy of the rAAV2/1-hVMD2-cBEST1-transduced regions revealed green autofluorescence in individual photoreceptor cells, patchy to generalized loss of cone photoreceptors and
mislocalization of both cone and rod opsin in treated areas (Fig. 6). Mislocalized rod opsin was seen in the inner segments (IS), outer nuclear layer (ONL) and in the outer plexiform layer, whereas the misrouted L/M & S opsin in some of the remaining cones were detected only in the ONL of rAAV2/1-hVMD2-cBEST1-injected areas (Fig. 6). In contrast, bestrophin1 expression mediated by the rAAV2/2-hVMD2-cBEST1 construct did not result in any photoreceptor, RPE or retinal abnormalities (Fig. 6). There was no evidence of any inflammatory response in any of the injected eyes.

Furthermore, co-expression of the canine endogenous and human BEST1 transgene was tested in the wild-type dog retina and evaluated at 4- and 6 weeks post injection. Both vector serotypes resulted in Best1 transgene expression in the RPE monolayer at 4 weeks p.i. (Fig. 7A,B). Again, whilst the co-expression of endogenous canine and human bestrophin1 transgene is well tolerated when mediated by rAAV2/2 serotype (Fig. 7B), introduction of rAAV2/1-hVMD2-cBEST1 vector construct with a low level of corresponding vector expressing GFP resulted in patchy to generalized loss of cones and rather robust green fluorescence emitted by individual photoreceptor cells that, presumably, were damaged (Fig 7A). There were no RPE/photoreceptor/retinal alterations found in the rAAV2/2-hVMD2-hBEST1-injected eyes at 4- or 6 weeks p.i. (Fig. 7B).

We then determined whether the RPE/retinal abnormalities observed with rAAV2/1-hVMD2-BEST1 were vector dose-dependent. To this end, the two vector serotypes carrying cBEST1 were administered to the cmr1 (C73T/R25X) carrier retinae that express half the normal levels of endogenous Best1 [13] (Fig. 7C,D). Delivery of rAAV2/1-hVMD2-cBEST1 (7.10x10^10 – 1.92x10^11 vg) or rAAV2/2-hVMD2-cBEST1 (4.44x10^11 vg) still resulted in bestrophin1 overexpression in cmr1+/- model at 4 weeks p.i. (Fig. 7C,D). Similar to the prior experiments with rAAV2/1, absence or reduced number of cones was observed in the rAAV2/1-hVMD2-cBEST1-injected region, albeit the routine H&E staining did not indicate structural damage to the tissue (Fig. 7C). In contrast, the cmr1+/- retina transduced with rAAV2/2 serotype showed no adverse effects (Fig. 7D).

Discussion

Progressive loss of central vision due to mutations in the BEST1 gene is one of the most common causes of hereditary early macular degeneration [21]. Despite the fact that this ocular condition was first described over a century ago [22], the causal
mechanism underlying its pathology is still poorly understood, and no cure is available. Here, we report studies on rAAV-mediated transgene expression using the human bestrophin promoter (hVMD2) in a large animal model as a first step towards developing gene augmentation therapy for human bestrophinopathies.

Although the stability and safety of rAAV2/2-mediated transgene expression in the canine retina has been previously assessed [19,23] and successfully translated to the human subjects (for review see [18]), this is the first study using rAAV2/1 and rAAV2/2 vectors incorporating the hVMD2 promoter to evaluate their potential use in RPE-directed gene therapy. Initially, the specificity, stability and safety of the constructs carrying GFP reporter gene controlled by the hVMD2 promoter were tested in the wild-type canine retina. A single subretinal injection of rAAV2/1-hVMD2-GFP or rAAV2/2-hVMD2-GFP specifically and exclusively targeted transgene expression to the RPE cells, and no significant difference in onset, expression level or stability was observed between the two serotypes. Most importantly, no adverse effects were noted, either in the RPE or neuroretina, with either vector construct secondary to the subretinal injection.

Following these encouraging results from the pilot study, the efficiency and BEST1 transgene expression was compared between the rAAV2/1 and rAAV2/2 serotypes. A dose range of 7.10×10^{10} – 2.00×10^{12} vg injected was tested in a set of 11 normal canine eyes delivering either canine or human BEST1 transgene. In each case, introduction of BEST1 into the wild-type retina induced bestrophin1 expression limited to RPE cells of the injected area. The eyes did not demonstrate any clinical abnormalities, and all injected areas appeared histologically normal with H&E staining. No inflammatory response was observed in any of the injected eyes. However, rAAV2/1 injected eyes with either human or canine BEST1, and containing low-level of corresponding vector expressing GFP reporter gene, revealed numerous photoreceptor cells, and, as expected, some RPE cells, that emitted green fluorescence. Based on their morphology and nuclear position, we interpreted the majority of the fluorescent photoreceptors to be cones. While this was confirmed, unexpectedly, we also found with photoreceptor specific immunolabeling that in all rAAV2/1-hVMD2-BEST1-treated areas there was a patchy to generalized loss of cones as well as mislocalization of cone and rod opsins. The loss of cones observed in all rAAV2/1-hVMD2-BEST1-injected regions was evident by lack of hCAR and L/M&S cone opsins immunoreactivity, as well as absence or reduced number of cone photoreceptor cells visualized by Nomarski DIC microscopy (data not shown). Such photoreceptor toxicity was not observed when using the rAAV2/2 vector at the same dosage level, or when using comparable doses of either rAAV2/1 or rAAV2/2 expressing only the GFP transgene and regulated by the hVMD2 promoter. We previously have found cone-specific damage in the canine retinae transduced with high doses (1.51–4.79×10^{13} vg/ml) of rAAV2/5-GFP vectors with the hGRK1 or CBA promoters [24]. These vector doses, however, were ~10,000 fold higher than the doses of GFP containing vector used to delimit the injected areas.

To exclude a vector-dose effect, the two vector serotypes were evaluated in asymptomatic cmr1 (C73T/R25X) carrier retinae that express only half the normal levels of endogenous Best1 [13]. The extent of cone-selective damage caused by rAAV2/1 transduction was comparable to that detected in the wild-type tissue. It is not clear at this time whether the damage and loss of cones was a direct effect, i.e. resulted from transduction of cones with the...
vector, or an undefined indirect effect via RPE transduction. The interaction between rAAV2/1-hVMD2-BEST1 and the rAAV2/1-GFP reporter construct cannot be ruled out, although the rAAV2/1-hVMD2-GFP vector construct by itself proved to be non-toxic to the retina. Furthermore, the effect of rAAV2/1 serotype capsid and its interaction with cell surface receptors cannot be eliminated either and might influence transduction pattern and, consequently, the delicate microenvironmental balance of the interphotoreceptor matrix. Considering that transgene expression levels are dose-dependent, and the physiological level of Best1 expression in the wild-type RPE cells are relatively low and limited to the basolateral plasma membrane, determination of a lower, safer and effective dosages of rAAV2/1-hVMD2-BEST1, without GFP admixture, may be important for future analysis. Because of the observed rAAV2/1-hVMD2-BEST1-associated cone toxicity this vector-promoter combination was not evaluated further in the present study. However, it will be a subject of more in depth future investigations.

It important to consider the cone-selective damage found in the canine retina in the context of future pre-clinical safety studies. While non-human primates or pigs have very distinct cones that are readily visualized by conventional histopathology in H&E stained sections, cones in dogs, mice and rats are difficult to identify, and damage to these cells, in the absence of a generalized photoreceptor atrophy, may go unrecognized. For that reason, we would suggest that specific immunolabeling of cones should be incorporated in safety assessments.

This work provides evidence that bestrophin1 overexpression mediated by rAAV2/2 serotype has no adverse effects on the RPE or retina, and BEST1 transgene expression is RPE-specific and stable. There was no evidence of retinal toxicity in the four eyes that have been followed for 4–6 weeks post injection. Additionally, one wild-type eye treated with rBEST1 transgene was followed for 6 months p.i. and also showed no evidence of toxicity. These preliminary results suggest that Best1 overexpression in the RPE results in no adverse effects. However, ongoing long-term studies on rAAV2/2-hVMD2-BEST1-mediated overexpression need to be concluded. Our findings to date strongly suggest that this approach is safe and might be useful in a mutation-independent basis. Thus, gene augmentation alone might be applied to all

Figure 3. Comparison of rAAV2/1- and rAAV2/2-mediated GFP expression in the wild-type canine retina. Immunohistochemical assessment of rAAV2/1-hVMD2-GFP (2.63 × 10^{11} vg) (A) and rAAV2/2-hVMD2-GFP (9.11 × 10^{10} vg) (B) injected retinas 6 weeks post injection. GFP expression (native expression = green; anti-GFP antibody = red) is shown only in the first row of images; selected retinal and RPE proteins were evaluated by antibody labeling. RPE cells expressed Best1 and RPE65 proteins; the structure of cone photoreceptors was demonstrated by hCAR and LM & S opsin labeling, while rods were assessed based on Rho localization. In all cases, protein expression was normal, specific and comparable to the non-injected eyes (data not shown), irrespective of the recombinant vector serotype used. Preservation of the retinal structure is demonstrated by H&E. RPE: retinal pigment epithelium, OS: photoreceptor outer segments; IS: photoreceptor inner segments; ONL: outer nuclear layer; INL: inner nuclear layer; cell nuclei were stained with DAPI; vg: vector genomes injected; scale bar: 40 μm.

doi:10.1371/journal.pone.0075666.g003
autosomal recessive and to those autosomal dominant mutations resulting in protein haploinsufficiency [25]. It is still to be proven whether gene augmentation alone is effective in cases where a dominant negative effect is suspected or whether the combination of mRNA silencing/resistant replacement strategy might be necessary [26–27]. Surprisingly, gene augmentation alone has been used successfully in the canine model of X-linked retinitis pigmentosa caused by RPGRORF15 microdeletion that resulted from a putative toxic gain of function [25,28]. Fortunately for bestrophinopathies it is possible to model the human and canine mutations in vitro and determine the optimal therapeutic approach [13].

Co-expression of canine endogenous and rAAV2/2-mediated human BEST1 transgene is well tolerated in the wild-type retina. This strengthens the model system even more and will facilitate the

![Figure 4. Evaluation of rAAV2/1- and rAAV2/2-mediated BEST1 transgene expression in the canine retina. (A) Comparison of two normal canine eyes that received subretinal injection of rAAV2/1 (1.94×10^{11} vg) and a spike-in of corresponding vector expressing GFP (3.81×10^9 vg) or rAAV2/2 (3.92×10^{11} vg) expressing canine BEST1 under control of human VMD2 promoter. The outlines of the injected areas detectable in NIR mode and more evident in AF mode for rAAV2/1 (arrowheads) corresponded to the bleb formed immediately after injection (insets). The arrows indicate retinotomy sites. (B) Retinal thickness profiling done by manual segmentation across the bleb boundaries revealed no significant changes 4 weeks p.i. with either vector construct. High-resolution OCT images were obtained using a 30° lens; NIR and AF images were captured using a 55° lens; vg: vector genomes injected; p.i.: post injection.

doi:10.1371/journal.pone.0075666.g004]
translational studies of Best1 therapy in the future. Proof of concept studies in cmr-affected dogs are currently in progress. Many canine diseases have clinical and molecular human counterparts [29–30]. The latest successes using rAAV-mediated gene augmentation therapy, first evaluated in large animal models [19,23] and then translated to clinical use [15–18], have paved a way for considering recombinant AAV vectors for treatment of other human retinopathies previously considered untreatable. Our study on rAAV-mediated BEST1 transgene expression in the canine RPE represents a first step towards gene augmentation therapy for bestrophinopathies. The unique combination of a spontaneous animal model on a stable genetic background with anatomical and phenotypic similarities to the human eye provides the exceptional opportunity to develop and test treatment options that can rapidly be translated to the clinic.

Materials and Methods

Animals

Twenty-nine eyes of young adult crossbred controls (23 dogs; n = 29 eyes) or three cmr1 carriers (n = 5 eyes) were used in this study (Tab. S1). All animals were bred and maintained at the Retinal Disease Studies Facility (RDSF), Kennett Square, PA and supported by facility grants from FFB and NEI/NIH EY06855. The studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The protocols were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania (IACUC Protocol #s 801870, 803422). All efforts were made to improve animal welfare and minimize discomfort.

Vector production

The human VMD2 promoter driving “humanized” GFP reporter [31] or BEST1 gene was evaluated in recombinant adeno-associated virus serotypes 1 (rAAV2/1) or 2 (rAAV2/2). Briefly, the hVMD2 promoter [32] (courtesy of D. J. Zack, Johns Hopkins University) was ligated into a recombinant AAV vector plasmid containing GFP or cBEST1 or hBEST1, SV40 splice donor/acceptor sites and polyadenylation signal (Fig. S1). The resulting plasmid constructs, hVMD2-GFP, hVMD2-cBEST1 or hVMD2-hBEST1 were then packaged into rAAV using standard vector preparation methods [31,33] and titrated for DNase-resistant vector genomes by RT-PCR relative to a standard using oligonucleotides targeting the SV40 polyadenylation signal (Forward: 5′-TTT GTG AAA TTT GTG ATG CT-3′; Reverse: 5′-TGA ATG CAA TTG TTG TTG TT-3′). The reaction mix was set up using iQ SYBR® Green Supermix (Bio-Rad Laboratories, Hercules, CA) and performed in a MyiQ™ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). Titers were calculated using the MyiQ™ Optical System Software, (Bio-Rad Laboratories Hercules, CA). The standard used for the Real-Time PCR was a rAAV with a known titer that was independently verified by PCR, dot blot and Infectious Center Assay (Vector Core Facility, University of Florida). Finally, the purity of the vector was validated using three standard assays. First, by silver-stained SDS-PAGE to confirm presence of the three capsid proteins; secondly, by assay screening for bioburden by spreading 10 µl of the final product on a non-selective LB-agar plate; and lastly, the final product was assayed for endotoxins using the Endosafe-PTS, portable test system (Charles River Laboratories, Charleston, SC, USA). For the rAAV2/1-hVMD2-BEST1 vectors with GFP spike-in, a portion of vector plasmid was used to package the GFP transgene. The amount of final GFP virus in the ad-mixture was determined by RT-PCR tittering with oligonucleotides targeted GFP cDNA. The average titer of the GFP component was 2.5×10^9 vg/ml, with a range of 1.05×10^9 to 3.81×10^9 vg/ml. Viral vector stocks were kept at −80°C in Balance Salt Solution (BSS; Alcon, Fort Worth, TX, USA), and all subsequent dilutions were prepared using BSS.
Subretinal injection and postoperative procedures

Subretinal injections of rAAV2/1 or rAAV2/2, carrying the GFP reporter or BEST1 wild-type cDNA sequence (canine or human), were performed under general anesthesia following previously published procedures [24–25,34]. A total volume of 90–200 μl of the viral vector solution, with different vector genome concentrations, was injected subretinally with a RetinaJect subretinal injector (SurModics Inc., Eden Prairie, MN, USA) under direct visualization with an operating microscope via a transvitreal approach without vitrectomy (Tab. S1). Each injection was directed to the superior temporal quadrant of the eye, a region with a uniform density of cone photoreceptors [35]. Fundus visualization was achieved with either a Machemer magnifying vitrectomy lens (OMVI; Ocular Instruments Inc., Bellevue, WA, USA), or a vitreoretinal surgery contact lens (AcrivetVit.Lens; Acrivet, Salt Lake City, UT, USA). Directly after injection, formation of a subretinal bleb was documented. An anterior chamber paracentesis was performed immediately after injection to prevent increase in intraocular pressure, followed by subconjunctival injection of 4 mg of triamcinolone acetonide.

Ophthalmic examinations, including biomicroscopy, indirect ophthalmoscopy and fundus photography, were conducted on a regular basis throughout the injection-endpoint evaluation time.

Figure 6. Consequences of rAAV2/1- and rAAV2/2-induced BEST1 transgene expression in vivo. Histological and immunohistochemical evaluation of wild-type canine retinae injected with rAAV2/1-hVMD2-cBEST1 (2.63 × 10^{11} vg) and a spike-in of corresponding vector expressing GFP (2.5 × 10^9 vg) or rAAV2/2-hVMD2-cBEST1 (4.44 × 10^{11} vg) in comparison to the non-injected control. H&E staining did not reveal any histological changes with either vector serotype. Both vectors induced bestrophin1 overexpression in the RPE cells 4 weeks post injection (Best1, red). While no abnormalities were observed in rAAV2/2-transduced retina, the rAAV2/1 serotype caused fluorescence in individual photoreceptor cells (green), occasional mislocalization of cone and rod opsins (arrowheads) and patchy loss of cone photoreceptors (arrows) in the rAAV2/1-hVMD2-cBEST1-injected area. RPE: retinal pigment epithelium, OS: photoreceptor outer segments; IS: photoreceptor inner segments; ONL: outer nuclear layer; INL: inner nuclear layer. Cell nuclei were stained with DAPI; vg: vector genomes injected; scale bar: 40 μm and applies to all panels.
doi:10.1371/journal.pone.0075666.g006
interval. Postoperative topical medication included application of atropine sulfate 1% ophthalmic ointment twice daily for 8 days, followed by once daily for 3 days; and neomycin/ polymyxin B sulfate/ dexamethasone ophthalmic ointment twice daily for 8 days, then once daily for 6 days. Systemic antibiotics (amoxicillin trihydrate/ clavulante potassium 12.5 mg/kg) were given orally twice daily for 3 days, and prednisone tablets (1 mg/kg) were administered twice daily for 9 days, followed by once daily for 1 week.

In vivo retinal imaging

Imaging was performed under general anesthesia using a cSLO/sdOCT instrument (Spectralis™ HRA/OCT, Heidelberg, Germany) on a bi-monthly basis. En face imaging was done using near infrared mode (NIR) to register fundus changes, while the native GFP expression was documented using short-wavelength autofluorescence mode (AF); both modes with a 55° lens. Spectral-domain optical coherence tomography (sd-OCT) was performed with linear and raster scans using a 30° lens.

**Figure 7.** rAAV-mediated BEST1 transfer to the retinal pigment epithelium and cone toxicity associated with rAAV2/1 vector serotype. (A-B) Co-expression of endogenous canine and human Best1 transgene in vivo. Histological and immunohistochemical analysis of wild-type canine retinas injected with rAAV2/1-hVMD2-hBEST1 (1.16 × 10^{12} vg) and a spike-in of corresponding vector expressing GFP (1.04 × 10^{10}) (A) and rAAV2/2-hVMD2-hBEST1 (8.82 × 10^{11} vg) (B) at 4 weeks post injection. No structural abnormalities were seen by H&E staining in any of the samples. In the retina transduced with rAAV2/1 capsid serotype (A), individual photoreceptor cells emitted green autofluorescence (arrowheads) as shown on the photomicrographs probed with anti-Best1, anti-L/M & S opsins and anti-hCAR (red) (A). Cone-specific labeling revealed loss of cone photoreceptors (arrows) only in the areas transduced with rAAV2/1 vector serotype (A). Co-expression of endogenous canine bestrophin1 and human BEST1 transgene was well tolerated when injected with rAAV2/2 serotype and no abnormalities were noted (B). (C-D) Comparison of rAAV2/1- and rAAV2/2-mediated cBEST1 transgene expression in the cmr1 (C31T/R25X) carrier retina. Histological and immunohistochemical evaluation of cmr1<sup>+/−</sup> retinae injected with rAAV2/1-hVMD2-cBEST1 (1.92 × 10^{11} vg) and a spike-in of corresponding vector expressing GFP (1.74 × 10^{10}) (C) and rAAV2/2-hVMD2-cBEST1 (4.44 × 10^{11} vg) (D) at 4 weeks post injection. No morphological abnormalities were detected by H&E staining between the two capsid serotypes (C-D). Sporadic autofluorescent cells (green) were observed in IS and ONL layers (C, arrowheads), and cone-specific immunolabeling (L/M & S opsins and anti-hCAR in red) revealed focal loss of cone photoreceptors (arrows) within the rAAV2/1-hVMD2-cBEST1-injected area (C). rAAV2/2-mediated cBEST1 transfer to the cmr1<sup>+/−</sup> retina results in bestrophin1 overexpression in the RPE (D, Best1 in red) with no adverse effects in the retinal tissue (D). RPE: retinal pigment epithelium; OS: photoreceptor outer segments; IS: photoreceptor inner segments; ONL: outer nuclear layer; INL: inner nuclear layer. Cell nuclei were stained with DAPI; vg: vector genomes injected; scale bar: 40 μm and applies to all panels.

doi:10.1371/journal.pone.0075666.g007
Linear scans were placed across regions of interest and images were averaged (20 ART) and taken in a 30 degree area line. Raster scans covered a 30×20 degree retinal areas with a 49 sequential B-scans, each one separated by 120 μm and with the average of 9 ART. The representative OCT scans were manually segmented to identify canine ELM and measure the ELM-ILM thickness.

Immunohistochemistry

Histological assessment using standard H&E staining and immunohistochemical analyses were performed on 10 μm cryosections using standard protocols [24,36]. Antibodies directed against GFP, Best1, RPE65, rod opsin, human cone arrestin, red/green cone opsin and blue cone opsin were used in single immunolabeling reactions and visualized with Alexa Fluor 568 nm goat anti-rabbit or goat anti-mouse secondary antibody; cell nuclei were stained with DAPI. Details of antibodies, dilution and source are in Table S2. Slides were mounted (Gelvatol, Sigma-Aldrich, St. Louis, MO, USA) and examined with epifluorescence or transmitted light microscopy (Axioplan; Carl Zeiss Meditec).

Confocal microscopy

Confocal images were acquired on a Leica TCS-SP5 tunable spectral confocal and multi-photon system with a Leica DM 6000 CFS upright microscope (Leica Microsystems, Wetzlar, Germany) through a HCX PL APO 40×(N.A. 1.25) or 60×(N.A. 1.40) oil immersion objectives. Alexa Fluor 568 was excited at 543 nm laser line and emission collected at 574–700 nm in sequential scanning mode by the tunable internal detectors. DAPI was excited with multi-photon at 750 nm produced by a Coherent Chameleon Ultra II Tissapphire pulse laser (Santa Clara, CA, USA) and emission was collected at 380–500 nm.

Acknowledgments

The authors thank Karla Carlisle and the Retinal Disease Studies Facility staff for animal care, Emily Dutrow and Julianna Slavik for excellent technical assistance, Al S. Lewin (University of Florida) for helpful discussions and suggestions, W. Clay Smith (University of Florida) for anti-GFP antibody, C.M. Craft (University of Southern California) for anti-hCAR antibody, Mary Leonard (Biomedical Art & Design, University of Pennsylvania) for assistance in graphic design, and Lydia Melnyk for editorial help and research coordination.

Supporting Information

Figure S1 Schematic diagrams of plasmid constructs used for rAAV2-hVMD2-GFP and rAAV2-hVMD2-BEST1 vectors production. (A) Map of the pTR-VMD2-GFP plasmid used to produce the rAAV2/1-hVMD2-GFP and rAAV2/2-hVMD2-GFP vector constructs. (B) Map of the pTR-VMD2-BEST1 plasmid used to produce the rAAV2/1-hVMD2-cBEST1, rAAV2/2-hVMD2-cBEST1, rAAV2/1-hVMD2-hBEST1 and rAAV2/2-hVMD2-hBEST1 vector constructs. TR: AAV2 inverted terminal repeats; VMD2: human VMD2 promoter [32]; SV40 SD/SA: SV40 late viral gene 16S/19S splice donor and acceptor signal; hGFP: “humanized” green fluorescence protein reporter[31]; BEST1: coding sequence of wild-type canine BEST1 or wild-type human BEST1 gene; SV40 (poly A) and bGH poly (A): polyadenylation signals; HSK-tk: thymidine kinase promoter of the herpes simplex virus; Neo R: coding sequence of the neomycin resistance gene. (TIF)

Figure S2 Transduction efficiency of rAAV2/1 and rAAV2/2 vectors carrying GFP reporter under control of human VMD2 promoter. Comparison of GFP expression levels induced by rAAV2/1 (2.63×10^{11} vg) or rAAV2/2 (9.11×10^{10} vg) at 6 weeks p.i. Native GFP expression (green) appeared more pronounced in the rAAV2/1 transduced RPE cells as confirmed by a dilution series of anti-GFP antibody (red). Expression levels induced with rAAV2/2 were detectable up to 1:75,000 dilution (left panel), while the rAAV2/2-mediated expression could not be visualized beyond a 1:50,000 dilution (right panel). Considering the difference in total virus genomes injected, however, both vectors appear to be qualitatively similar in transduction efficiency and both specifically target transgene expression to the RPE cell monolayer. Cell nuclei were stained with DAPI; vg: vector genomes injected; p.i.: post infection; scale bar: 40 μm. (TIF)

Figure S3 Monitoring the bleb kinetics and spatial extent of single subretinal injection in the canine fundus. (A–D) rAAV2/1-hVMD2-cBEST1-injected eye (1.94×10^{11} vg/ml) with a spike-in of corresponding vector expressing GFP (3.81×10^{7} vg/ml); a higher magnification figure of part of the fundus is shown in Fig. 4A. Composite fundus images NIR 55° 82°×56° (A) and AF 55° 98°×58° (B) captured 4 weeks after single subretinal injection of 150 μl. Note the GFP spiked area visible in autofluorescence mode (B) delimiting the spatial extent of injection (arrowheads). The arrow indicates retinotomy site. (C–D) Single (C) and double (D) immunolabeling of anti-GFP (green) and anti-hCAR (red). The GFP-positive cells scattered in the RPE monolayer corresponded to the injection boundaries outlined by AF mode (B). This area shows minimal damage to cones. Cell nuclei were stained with DAPI; scale bar: 40 μm. (TIF)

Table S1 Summary of injected subjects used in the studies. Recombinant adenovirus vectors and dosage analyzed in total of 34 canine eyes. Eyes #: number of eyes injected per each type of vector; vg: vector genomes injected; Evaluation time point: post injection time by endpoint evaluation. p.i.: post injection. (DOCX)

Table S2 List of primary antibodies used for immunolabeling. Tissue sections were washed in 1XPBS/0.25% TX-100 for 5 minutes and blocked for 1 h (10% normal goat serum, 1XPBS/0.25% TX-100, 0.05% sodium azide). Overnight incubation (at 4°C) with antibodies listed in the table was followed by three 1XPBS washes and incubation with 1:200 Alexa Fluor 568 nm goat anti-rabbit (A1036, Invitrogen, Carlsbad, CA, USA) or goat anti-mouse (A1031, Invitrogen, Carlsbad, CA, USA) secondary antibody, respectively, for 1 h at room temperature. (DOC)

Author Contributions

Conceived and designed the experiments: KEG BZ. VAC SLB WWH WAB GDA. Performed the experiments: KEG BZ AMK SI VAC. Analyzed the data: KEG BZ AMK SI VAC SLB WWH WAB GDA. Contributed reagents/materials/analysis tools: KEG BZ AMK SI VAC SLB WWH WAB GDA. Wrote the paper: KEG BZ.
References

1. Petrokutnik K, Koisti MJ, Bakall B, Li W, Xie G, et al. (1998) Identification of the gene responsible for Best macular dystrophy. Nat Genet 19: 241–247.
2. Pietanta MJ, Aleman TS, Cideciyan AV, Sunness JS, Li Y, et al. (2003) In vivo histopathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res 76: 203–211.
3. Kinnick TR, Mullins RF, Dev S, Leys M, Mackey DA, et al. (2011) Autosomal recessive vitelliform macular dystrophy in a large cohort of vitelliform macular dystrophy patients. Retina 31: 301–305.
4. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hellyfield JG, et al. (2008) Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A 97: 12750–12753.
5. Sun H, Tsunenari T, Yau KW, Nathans J (2002) The vitelliform macular dystrophy protein defines a new family of chloride channels. PLoS Med 1: e193.
6. Rosenthal R, Bakall B, Kinnick T, Peachey N, Wimmers S, et al. (2005) Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells. FASEB J 20: 178–180.
7. Milenkovic VM, Krejcova S, Reichhart N, Wagner A, Straus O (2011) Interaction of bestrophin-1 and Ca2+ channel β-subunits: identification of new binding domains on the bestrophin-1 C-terminus. J Proteome Res 10: e13964.
8. Hartzell HC, Qi Z, Yu K, Xiao Q, Chien LT (2008) Molecular physiology of bestrophins: multifunctional membrane proteins linked to best disease and other retinopathies. Physiol Rev 88: 639–672.
9. Bont PJ, Klevering BJ, Leroy BP, Hoyng CB, Keunen JE, et al. (2009) The prevalence of retinal photoreceptor outer segment abnormalities in Best macular dystrophy patients. Retina 29: 1033–1038.
10. Milenkovic VM, Rothel E, Weber BH, Straus O (2011) Disease-associated missense mutations in bestrophin-1 affect cellular trafficking and anion conductance. J Cell Sci 124: 2988–2996.
11. Guziewicz KE, Zangerl B, Lindsaar SJ, Mullins RF, Sandmeyer LS, et al. (2007) Bestrophin gene mutations cause canine multifocal retinopathy: a novel animal model for best disease. Invest Ophthalmol Vis Sci 48: 1959–1967.
12. Zangerl B, Wickstrom K, Slavik J, Lindsaar SJ, Ahonen S, et al. (2010) Assessment of canine BEST1 variations identifies new mutations and establishes an independent bestrophinopathy model (cmr3). Mol Vis 16: 2791–2804.
13. Guziewicz KE, Slavik J, Lindsaar SJ, Aguirre GD, Zangerl B (2011) Molecular consequences of BEST1 gene mutations in canine multifocal retinopathy predict functional implications for human bestrophinopathies. Invest Ophthalmol Vis Sci 52: 4497–4505.
14. Guziewicz KE, Aguirre GD, Zangerl B (2012) Modeling the structural consequences of BEST1 missense mutations. Adv Exp Med Biol 723: 611–618.
15. Bannasch P, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358: 2231–2239.
16. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, et al. (2006) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 355: 2240–2248.
17. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, et al. (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979–990.
18. Jacobson SG, Cideciyan AV, Ramakaran R, Hron E, Schwartz SB, et al. (2012) Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130: 9–24.
19. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, et al. (2005) Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12: 1072–1082.
20. Auricchio A, Kobinger G, Anand V, Hildinger M, O’Conner K, et al. (2001) Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10: 3075–3081.
21. Bittner A, Schatz P, Mizrahi-Meissonnier L, Sharon D, Rosenberg T (2012) Frequency, genotype, and clinical spectrum of best vitelliform macular dystrophy: data from a national center in Denmark. Am J Ophthalmol 154: 403–412.
22. Best F (1905) Ueber eine hereditaire Maculaauffektion. Z Augenheilk 13: 199–212.
23. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, et al. (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 29: 92–95.
24. Beltran WA, Boye SL, Boye SE, Chiodo VA, Levin AS, et al. (2010) rAAV2/5 gene-targetting to rods: dose-dependent efficiency and complications associated with different promoters. Gene Ther 17: 1162–1174.
25. Beltran WA, Cideciyan AV, Levin AS, Iwabe S, Khanna H, et al. (2012) Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A 109: 2132–2137.
26. Kiang AS, Palfi A, Ader M, Kruma PF, Millington-Ward S, et al. (2005) Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther 12: 555–561.
27. Gorbatiuk M, Justilen V, Liu J, Hauswirth WW, Levin AS (2007) Suppression of mouse rhodopsin expression in vivo by AAV-mediated siRNA delivery. Vision Res 47: 1202–1208.
28. Zhang Q, Acland GM, Wu WX, Johnson JL, Pearce-Kelling S, et al. (2002) Different RPRGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. Hum Mol Genet 11: 993–1003.
29. Aguirre GD and Acland GM (2006) Models, Mutants and Man: Searching for Unique Phenotypes and Genes in the Dog Model of Inherited Retinal Degeneration. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. 291–325pp.
30. Miyadera K, Acland GM, Aguirre GD (2012) Genetic and phenotypic variations of inherited retinal diseases in dogs: the power of within- and across-breed studies. Mamm Genome 23: 40–61.
31. Zolotukhin S, Potter M, Hauswirth WW, Guy M, Muyuczka N (1996) A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70: 4646–4654.
32. Eumji N, Oshima Y, Li Y, Campochiaro PA, Zack DJ (2004) Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem 279: 19064–19073.
33. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, et al. (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973–983.
34. Komaromy AM, Varner SE, de Juan E, Acland GM, Aguirre GD (2006) Application of a new subretinal injection device in the dog. Cell Transplant 15: 511–519.
35. Moon KT, Petersen-Jones SM, Williamson H, Williams DL, Luthert PJ, et al. (2000) Topographical characterization of cone photoreceptors and the area centrals of the canine retina. Mol Vis 14: 2518–2527.
36. Beltran WA, Rohrer H, Aguirre GD (2005) Immunolocalization of ciliary neurotrophic factor receptor alpha (CNTF-Ralpha) in mammalian photoreceptor cells. Mol Vis 11:232–244.
Table S1. Summary of injected subjects used in the studies.

| Vector construct      | Serotype | Promoter | Transgene | Titer vg/ml       | Eyes # | Volume | vg injected | Evaluation time point |
|-----------------------|----------|----------|-----------|-------------------|--------|--------|-------------|-----------------------|
| rAAV2-hVMD2-GFP       | 1        | hVMD2    | GFP       | 1.17x10^{12} - 2.20x10^{13} | 1      | 120µl  | 2.64x10^{11} | 2 weeks p.i.          |
|                       |          |          |           |                   |        | 150µl  | 3.30x10^{11} | 2 weeks p.i.          |
|                       |          |          |           |                   |        | 160µl  | 2.80x10^{11} | 2 weeks p.i.          |
|                       |          |          |           |                   |        | 120µl  | 1.40x10^{11} | 4 weeks p.i.          |
|                       |          |          |           |                   |        | 180µl  | 1.58x10^{11} | 4 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 2.63x10^{11} | 4 weeks p.i.          |
|                       |          |          |           |                   | 1      | 185µl  | 3.35x10^{12} | 4 weeks p.i.          |
|                       |          |          |           |                   | 1      | 190µl  | 3.44x10^{12} | 4 weeks p.i.          |
|                       |          |          |           |                   | 1      | 120µl  | 1.40x10^{11} | 6 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 1.76x10^{11} | 6 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 2.63x10^{11} | 6 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 1.31x10^{11} | 6 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 9.11x10^{10} | 2 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 9.11x10^{10} | 2 weeks p.i.          |
|                       |          |          |           |                   | 1      | 200µl  | 1.21x10^{11} | 4 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 9.11x10^{10} | 6 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 9.11x10^{10} | 6 weeks p.i.          |
|                       |          |          |           |                   | 1      | 150µl  | 9.11x10^{10} | 6 months p.i.         |
### Table S1 Continued

| Vector construct         | Serotype | Promoter | Transgene | Titer vg/ml | Eyes # | Volume | vg injected | GFP component | Evaluation |
|--------------------------|----------|----------|-----------|-------------|--------|--------|-------------|---------------|------------|
| rAAV2-hVMD2-BEST1        | 1        | hVMD2    | cBEST1    | 1.29x10^{12} - 1.11x10^{13} | 1      | 120µl  | 2.63x10^{11} - 1.74x10^{9} | - 3.81x10^{9} | 4 weeks p.i. |
|                          |          |          |           |             |        |        |             |               |            |
|                          |          |          |           |             | 1      | 140µl  | 1.53x10^{11} |               | 4 weeks p.i. |
|                          |          |          |           |             | 1      | 170µl  | 2.19x10^{11} |               | 4 weeks p.i. |
|                          |          |          |           |             | 1      | 180µl  | 2.00x10^{12} |               | 4 weeks p.i. |
|                          |          |          |           |             | 1      | 180µl  | 2.00x10^{12} |               | 4 weeks p.i. |
|                          |          |          |           |             | 1      | 150µl  | 1.94x10^{11} |               | 6 weeks p.i. |
|                          | 1*       |          |           |             | 90µl   | 1.92x10^{11} |               |               | 4 weeks p.i. |
|                          | 1*       |          |           |             | 100µl  | 7.10x10^{10} |               |               | 4 weeks p.i. |
|                          |          |          |           |             | 100µl  | 1.07x10^{11} |               |               | 4 weeks p.i. |
| rAAV2-hVMD2-BEST1        | 1        | hVMD2    | hBEST1    | 6.85x10^{12} | 1      | 170µl  | 1.16x10^{12} | 1.04x10^{9}   | 4 weeks p.i. |
|                          |          |          |           |             |        |        |             |               |            |
|                          |          |          |           |             | 1*     | 150µl  | 1.03x10^{12} |               | 6 weeks p.i. |
| rAAV2-hVMD2-BEST1        | 2        | hVMD2    | cBEST1    | 2.61x10^{12} | 1      | 170µl  | 3.92x10^{11} |               | 6 weeks p.i. |
|                          |          |          |           |             |        |        |             |               |            |
|                          |          |          |           |             | 1      | 150µl  | 3.92x10^{11} |               | 6 months p.i. |
|                          | 1*       |          |           |             | 170µl  | 4.44x10^{11} |               |               | 4 weeks p.i. |
| rAAV2-hVMD2-BEST1        | 2        | hVMD2    | hBEST1    | 5.88x10^{12} | 1      | 150µl  | 8.82x10^{11} |               | 4 weeks p.i. |
|                          |          |          |           |             |        |        |             |               |            |
|                          |          |          |           |             | 1      | 170µl  | 1.00x10^{12} |               | 6 weeks p.i. |

(*) represents cmr1 carrier eyes; p.i. - post injection
Table S2. List of primary antibodies used for immunolabeling.

| Antibody                        | Dilution          | Source                                                                 |
|---------------------------------|-------------------|------------------------------------------------------------------------|
| Rabbit polyclonal anti-GFP      | 1:1000-1:75000    | Courtesy of W.C. Smith (University of Florida)                         |
| Mouse monoclonal anti-GFP       | 1:1000            | MAB3580, Chemicon, Billerica, MA, USA                                  |
| Mouse monoclonal anti-Best1     | 1:400             | Ab2182, Abcam, Cambridge, MA, USA                                      |
| Mouse monoclonal anti-RPE65     | 1:500             | NB100-355, Novus Biologicals, LLC, Littleton, CO, USA                 |
| Mouse monoclonal anti-Rho       | 1:1000            | MAB5316, Millipore, Billerica, MA, USA                                |
| Rabbit polyclonal anti-hCAR     | 1:10000           | Courtesy of C.M. Craft (University of Southern California)             |
| Rabbit polyclonal anti-red/green opsin | 1:100     | AB5405, Millipore, Billerica, MA, USA                                 |
| Rabbit polyclonal anti-blue opsin | 1:5000         | AB5407, Millipore, Billerica, MA, USA                                 |